Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system
Shuyue Li, Tao Ling, Yan Liu, Jun Li · 2026
Read Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system by Shuyue Li, Tao Ling, Yan Liu, Jun Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12812994.txt.
Description
Shuyue Li, Tao Ling, Yan Liu, and Jun Li analyze nerve side effects of proteasome inhibitor drugs in a US safety database, in a 2026 study. The three drugs treat multiple myeloma, a blood cancer, and are known to damage peripheral nerves. Their full nerve risk profile, including brain effects, was less clear.
The team mined more than two decades of adverse event reports and applied several statistical signal methods. Peripheral neuropathy was the most common nerve signal for all three drugs. One drug showed the strongest overall nerve signals, including a rare autonomic form. The others showed distinct rare signals. Sex and time-to-onset patterns were also examined.
Catalog record
| CREATOR | Shuyue Li, Tao Ling, Yan Liu, Jun Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |